Form 4: Replimune CMO Sells Shares for Tax Obligations

Replimune Group's Chief Medical Officer, Konstantinos Xynos, sold 7,248 shares of common stock at a weighted average price of $9.10 to cover tax withholding obligations related to RSU vesting.

Summary

• Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., reported a transaction involving the company's common stock.
• On November 17, 2025, Mr. Xynos disposed of 7,248 shares of common stock.
• The shares were sold at a weighted average price of $9.10 per share, with prices ranging from $8.88 to $9.26.
• The sale was a non-discretionary 'sell to cover' transaction to satisfy tax withholding obligations associated with the partial vesting of Restricted Stock Units (RSUs).
• Following this transaction, Mr. Xynos beneficially owns 139,685 shares of Replimune Group, Inc. common stock directly.
• The transaction was made in accordance with an irrevocable 'sell to cover' provision in the RSU award agreements and was not a discretionary sale by the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the explicit explanation that it's a non-discretionary 'sell to cover' for tax obligations mitigates any negative interpretation. It's a routine event for executives with RSU awards.

Positives

• The transaction was a non-discretionary 'sell to cover' to meet tax obligations, indicating it was a routine event rather than a discretionary sale based on a change in confidence.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, signifying a pre-planned and scheduled event.

Negatives

• An insider sale, even for tax purposes, can sometimes be misinterpreted by some investors as a lack of confidence, although this specific type of transaction is common and generally not a major concern.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market perception of insider sales, which could lead to minor, short-term negative sentiment if misunderstood.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an executive's stock transaction.

Management Comments

• The transaction reported herein was made in accordance with the irrevocable 'sell to cover' provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

Industry Context

This type of 'sell to cover' transaction is a routine and common occurrence for executives in publicly traded companies when Restricted Stock Units (RSUs) vest. It is a standard mechanism to satisfy tax liabilities incurred upon the vesting of equity awards and is not indicative of a change in the company's operational performance or an executive's confidence.

Comparison to Industry Standards

• The 'sell to cover' mechanism for RSU vesting is a widely adopted practice across various industries for executive compensation, aligning with standard corporate governance and tax compliance procedures.
• Many companies, including peers in the biotechnology and pharmaceutical sectors, utilize similar equity compensation structures and tax withholding methods for their executives.
• This transaction is comparable to similar filings by executives at companies like Moderna (MRNA) or BioNTech (BNTX) where RSU vesting often triggers non-discretionary sales for tax purposes.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction. Could lead to minor, short-term sentiment fluctuations if misunderstood.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The filing details a routine, non-discretionary 'sell to cover' transaction by a Chief Medical Officer to satisfy tax obligations upon RSU vesting. This is a common practice and does not reflect a change in the executive's confidence or the company's fundamentals, thus it provides no new information to alter an existing investment thesis. Investors should 'hold' their position based on this specific filing, awaiting more substantive operational or financial news.

Keywords

Replimune Group, REPL, Insider Transaction, Form 4, Stock Sale, Chief Medical Officer, RSU Vesting, Tax Withholding, Sell to Cover